Wertel I - Search Results

1

Telomeres and telomerase in endometrial cancer and hyperplasia.

Pańczyszyn A, Boniewska-Bernacka E, Włodarczyk K, Wertel I, Goc A. Pańczyszyn A, et al. Among authors: wertel i. Arch Med Sci. 2024 Mar 30;20(2):682-685. doi: 10.5114/aoms/186189. eCollection 2024. Arch Med Sci. 2024. PMID: 38757009 Free PMC article.

2

Analysis of RCAS1 immunoreactivity within hydatidiform mole cells and decidual cells according to the applied therapeutic strategy: surgery or surgery followed by chemotherapy.

Wicherek L, Basta P, Wertel I, Kojs Z, Malkowski B, Grabiec M, Pietrus M, Krystyna G. Wicherek L, et al. Among authors: wertel i. Gynecol Obstet Invest. 2012;73(2):106-12. doi: 10.1159/000328509. Epub 2012 Jan 24. Gynecol Obstet Invest. 2012. PMID: 22269478

3

Assessment of regulatory T cells, cytotoxic lymphocytes and dendritic cells in ovarian cancer patients before and after menopause.

Surówka JA, Wertel I, Polak G, Okła K, Bilska M, Kotarski J. Surówka JA, et al. Among authors: wertel i. Ginekol Pol. 2016;87(1):11-8. doi: 10.17772/gp/60976. Ginekol Pol. 2016. PMID: 27306463 Free article. English, Polish. No abstract available.

4

[Expression of lymphangiogenesis marker neuropilin-1 in different types of ovarian cancer].

Bednarek W, Mazurek-Kociubowska M, Sobstyl M, Wertel I, Czekierdowski A. Bednarek W, et al. Among authors: wertel i. Ginekol Pol. 2010 Mar;81(3):176-82. Ginekol Pol. 2010. PMID: 20486537 Polish.

5

[Expression of tumor necrosis factor-alpha (TNF-alpha) on peritoneal fluid mononuclear cells in women with endometriosis].

Gogacz M, Bogusiewicz M, Putowski L, Adamiak A, Wertel I, Jakowicki JA, Rechberger T. Gogacz M, et al. Among authors: wertel i. Ginekol Pol. 2008 Jan;79(1):31-5. Ginekol Pol. 2008. PMID: 18510047 Polish.

6

[Why ovarian cancer cells escape from immune surveillance?].

Wertel I, Okła K, Surówka J, Bilska M, Polak G, Bednarek W, Kotarski J. Wertel I, et al. Wiad Lek. 2017;70(1):74-80. Wiad Lek. 2017. PMID: 28343198 Review. Polish.

7

[Ferritin levels in the peritoneal fluid--a new endometriosis marker?].

Polak G, Wertel I, Tarkowski R, Morawska D, Nowakowski A, Kotarski J. Polak G, et al. Among authors: wertel i. Ginekol Pol. 2006 May;77(5):389-93. Ginekol Pol. 2006. PMID: 16958229 Polish.

8

[Selected mechanisms inducing resistance to immunotherapy in patients with ovarian cancer].

Pietrzyk N, Piętak P, Pawłowska A, Suszczyk D, Chudzik A, Kotarski J, Wertel I. Pietrzyk N, et al. Among authors: wertel i. Wiad Lek. 2019;72(7):1397-1402. Wiad Lek. 2019. PMID: 31398175 Polish.

9

[Characterization of chosen pro-angiogenic factors and anti-angiogenic therapies in ovarian cancer].

Wiśniewski K, Pawłowska A, Bobiński M, Okła K, Kotarski J, Wertel I. Wiśniewski K, et al. Among authors: wertel i. Wiad Lek. 2018;71(8):1603-1607. Wiad Lek. 2018. PMID: 30684347 Review. Polish.

10

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.

Suszczyk D, Skiba W, Zardzewiały W, Pawłowska A, Włodarczyk K, Polak G, Tarkowski R, Wertel I. Suszczyk D, et al. Among authors: wertel i. Int J Mol Sci. 2022 Oct 1;23(19):11607. doi: 10.3390/ijms231911607. Int J Mol Sci. 2022. PMID: 36232911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters